ARLINGTON, VA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)INFECTIOUS DISEASES SOCIETY OF AMERICA, founded in 1970, is a mid-sized nonprofit that reported $37.6M in total revenue in fiscal year 2023. Revenue grew 10% year-over-year, indicating healthy expansion.
THE INFECTIOUS DISEASES SOCIETY OF AMERICA (IDSA) IS A COMMUNITY OF OVER 12,000 PHYSICIANS, SCIENTISTS AND PUBLIC HEALTH EXPERTS WHO SPECIALIZE IN INFECTIOUS DISEASES. OUR PURPOSE IS TO IMPROVE THE HEALTH OF INDIVIDUALS, COMMUNITIES, AND SOCIETY BY PROMOTING EXCELLENCE IN PATIENT CARE, EDUCATION, RESEARCH, PUBLIC HEALTH, AND PREVENTION RELATING TO INFECTIOUS DISEASES.
IDWEEK ANNUAL CONFERENCE - IDWEEK 2023 IN BOSTON, MA, ATTRACTED A RECORD-BREAKING 12,000+ TOTAL ATTENDEES. THE MEETING IS THE WORLD'S PREMIER INFECTIOUS DISEASES EVENT. IDWEEK PROVIDES AN OPPORTUNITY...
IDWEEK ANNUAL CONFERENCE - IDWEEK 2023 IN BOSTON, MA, ATTRACTED A RECORD-BREAKING 12,000+ TOTAL ATTENDEES. THE MEETING IS THE WORLD'S PREMIER INFECTIOUS DISEASES EVENT. IDWEEK PROVIDES AN OPPORTUNITY FOR HEALTH PROFESSIONALS OF VARIED BACKGROUNDS TO LEARN FROM EACH OTHER'S KNOWLEDGE, EXPERIENCE AND EXPERTISE, FOR THE IMPROVEMENT OF PATIENT CARE AND PUBLIC HEALTH. THIS IS AN INCLUSIVE MEETING THAT OFFERS ACCESS TO INTERNATIONALLY RECOGNIZED LEADERS IN THE FIELD AND THE OPPORTUNITY TO NETWORK WITH THE MOST HIGHLY RESPECTED HEALTH PROFESSIONALS IN INFECTIOUS DISEASES, INCLUDING HIV.
CLINICAL INFECTIOUS DISEASES (CID), THE JOURNAL OF INFECTIOUS DISEASES (JID) AND OPEN FORUM INFECTIOUS DISEASES (OFID) ARE SCHOLARLY JOURNALS PUBLISHED BY IDSA IN PARTNERSHIP WITH AN OUTSIDE...
CLINICAL INFECTIOUS DISEASES (CID), THE JOURNAL OF INFECTIOUS DISEASES (JID) AND OPEN FORUM INFECTIOUS DISEASES (OFID) ARE SCHOLARLY JOURNALS PUBLISHED BY IDSA IN PARTNERSHIP WITH AN OUTSIDE PUBLISHER TO DISSEMINATE THE LATEST RESEARCH ON A VARIETY OF TOPICS IN THE FIELD TO MEMBERS AND SUBSCRIBERS. CID PUBLISHES ORIGINAL RESEARCH, REVIEWS AND PERSPECTIVES THAT ALL CLINICIANS CAN USE WHEN CARING FOR PATIENTS. CID COVERS THE CLINICAL PRESENTATION, DIAGNOSIS, TREATMENT AND PREVENTION OF THE FULL RANGE OF INFECTIOUS DISEASES. THE EVALUATION OF CURRENT AND NOVEL TREATMENTS, MICROBIOLOGY, IMMUNOLOGY AND POLICIES AS THEY RELATE TO PATIENT CARE ARE HIGHLY PRIORITIZED. PUBLISHED CONTINUOUSLY SINCE 1904, JID IS THE PREMIER GLOBAL JOURNAL FOR TRANSLATIONAL INFECTIOUS DISEASES SCIENCE. THE EDITORS WELCOME MAJOR ARTICLES AND BRIEF REPORTS DESCRIBING RESEARCH RESULTS ON MICROBIOLOGY, IMMUNOLOGY, EPIDEMIOLOGY, AND RELATED DISCIPLINES, ON THE PATHOGENESIS, DIAGNOSIS, AND TREATMENT OF INFECTIOUS DISEASES; ON THE MICROBES THAT CAUSE THEM; AND ON DISORDERS OF HOST IMMUNE RESPONSES. OFID PUBLISHES CLINICAL, TRANSLATIONAL AND BASIC RESEARCH IN A FULLY OPEN ACCESS, ONLINE JOURNAL. IT FOCUSES ON THE INTERSECTION OF BIOMEDICAL SCIENCE AND CLINICAL PRACTICE, WITH AN EMPHASIS ON KNOWLEDGE THAT COULD IMPROVE PATIENT CARE GLOBALLY. ARTICLES ARE WRITTEN BY EXPERTS IN THE FIELD, INCLUDING MEMBERS AND NON-MEMBERS, AND REVIEWED BY A PANEL OF LEADING MEDICAL EXPERTS BEFORE THEY ARE PUBLISHED.
IDSA WAS AWARDED A COOPERATIVE AGREEMENT TO SUPPORT THE CDC BY PROVIDING RESOURCES TO FRONTLINE HEALTH CARE PROFESSIONALS CARING FOR PATIENTS WITH COVID-19. THE PARTNERSHIP BRINGS NUMEROUS MEDICAL...
IDSA WAS AWARDED A COOPERATIVE AGREEMENT TO SUPPORT THE CDC BY PROVIDING RESOURCES TO FRONTLINE HEALTH CARE PROFESSIONALS CARING FOR PATIENTS WITH COVID-19. THE PARTNERSHIP BRINGS NUMEROUS MEDICAL SPECIALTIES TOGETHER TO SHARE RESOURCES AND TO PROVIDE THE LATEST INFORMATION AND GUIDANCE ON TREATING THOSE INFECTED WITH COVID-19 AND PREVENTING ITS SPREAD. THROUGH FUNDING FROM CDC, IDSA EXPERTS SUPPORT CDC'S CLINICAL CALL LINES, PROVIDING GUIDANCE TO HEALTH CARE PROVIDERS TREATING COVID-19 PATIENTS. THE COLLABORATION HAS ALSO FUNDED THE FLOURISHING COVID-19 REAL-TIME LEARNING NETWORK, AN ONLINE CENTER FOR FRONTLINE CLINICIANS TO LEARN, COLLABORATE AND SHARE TREATMENT BEST PRACTICES. IDSA'S COVID-19 PRACTICE GUIDELINES ON DIAGNOSTICS, TREATMENT AND MANAGEMENT ALSO RECEIVE FUNDING THROUGH THE GRANT. ADDITIONALLY, UNDER THE PARTNERSHIP, TWICE-MONTHLY CLINICIAN TELECONFERENCES PROVIDE HEALTH CARE PROFESSIONALS ACCESS TO EXPERTS WITH THE LATEST INFORMATION ON THIS EVOLVING VIRUS AS WELL AS AN OPPORTUNITY TO ASK QUESTIONS. THE CALLS FREQUENTLY DRAW MORE THAN 800 ATTENDEES.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $37,618,238 | $34,301,211 | +0.1% |
| Expenses | $37,463,898 | $32,853,700 | +0.1% |
| Net Income | $154,340 | $1,447,511 | -0.9% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| CHRISTOPHER BUSKY CAE | CHIEF EXECUTIVE OFFICER | 36.50 |
Officer
|
$571,440 | $56,143 | $640,631 |
| TY JOHNSON | CHIEF OPERATING OFFICER | 25.00 |
Officer
|
$291,719 | $20,646 | $434,274 |
| DANA WOLLINS | SVP, STRATEGY | 37.50 |
Key Emp
|
$289,970 | $26,441 | $316,411 |
| AMANDA JEZEK | SVP, POLICY & GOV. RELATIONS | 37.50 |
Key Emp
|
$286,139 | $21,485 | $307,624 |
| SANDRA VURA HARDWOOD | VP, MEETINGS AND EDUCATION | 37.50 |
Key Emp
|
$281,761 | $21,936 | $303,697 |
| FELICITY CLANCY | VP, MARKETING AND MEMBERSHIP | 37.50 |
Highest
|
$258,862 | $22,375 | $281,237 |
| SALANDRA THOMAS | VP, TALENT AND ORGANIZATIONAL DEVELOPMENT | 36.50 |
Highest
|
$241,118 | $19,578 | $266,617 |
| ANDREA WEDDLE | ED, HIVMA | 36.50 |
Key Emp
|
$243,666 | $14,935 | $264,592 |
| BARTON GROH | VP, FINANCE AND ADMINISTRATION | 32.50 |
Officer
|
$236,612 | $19,234 | $261,643 |
| GAYLE LEVY HARTMAN | SR. DIR., DIGITAL AND CONTENT STRATEGY | 37.50 |
Highest
|
$172,458 | $20,803 | $193,261 |
| JENNIFER MORALES | SR. DIR., PR & MARKETING | 37.50 |
Highest
|
$173,291 | $11,055 | $184,346 |
| RACHEL SHNEKENDORF | SR. DIR., EDUCATION | 37.50 |
Highest
|
$172,302 | $10,926 | $183,228 |
| CARLOS DEL RIO MD | IMMEDIATE PAST PRESIDENT | 2.00 |
Officer
Director
|
$45,000 | $0 | $45,000 |
| STEVEN K SCHMITT MD | PRESIDENT | 2.00 |
Officer
Director
|
$25,000 | $0 | $25,000 |
| TINA Q TAN MD FIDSA | PRESIDENT-ELECT | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| JEFFREY S DUCHIN MD FIDSA | SECRETARY THRU 05/2023 | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| JEANNE MARRAZZO MD FIDSA | TREASURER THRU 10/2023 | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| DAN P MCQUILLEN MD FIDSA | IMMEDIATE PAST PRESIDENT THRU 10/23 | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| MAXIMO O BRITO MD FIDSA | TREASURER A/O 10/2023 | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| ROBIN TROTMAN MD FIDSA | SECRETARY A/O 05/2023 | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| RONALD NAHASS MD | VICE PRESIDENT A/O 10/2023 | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| LILIAN M ABBO MD FIDSA | MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| ERIN BONURA MD | MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| CESAR A ARIAS MD FIDSA | MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| ROBIN HENRY DRETLER MD | MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| RANA CHAKRABORTY MD MSC DPHIL FID | MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| RAJESH T GHANDI MD FIDSA | MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| JASMINE MARCELIN MD FIDSA | MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| BONNIE M WORD MD FIDSA | MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| MATIFADZA HLATSHWAYO DAVIS MD MPH | MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| KAMI KIM MD | MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| ADA ADIMORA MD | MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| HEATHER C YUN MD | MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | No data | No data | No data | No data |
| 2023 | $37,618,238 | $37,463,898 | $68,105,366 | $154,340 |
| 2022 | $34,301,211 | $32,853,700 | $66,632,887 | $1,447,511 |
| 2021 | $31,558,220 | $22,830,570 | $64,244,197 | $8,727,650 |
| 2020 | $23,933,988 | $22,921,023 | $55,497,488 | $1,012,965 |
| 2019 | $26,129,626 | $24,070,932 | $44,627,539 | $2,058,694 |
| 2018 | $23,550,635 | $23,049,292 | $40,110,545 | $501,343 |
Compare INFECTIOUS DISEASES SOCIETY OF AMERICA with other nonprofits in Virginia and across the country.